Cargando…
Effects of Bifidobacterium animalis ssp. lactis 420 on gastrointestinal inflammation induced by a nonsteroidal anti‐inflammatory drug: A randomized, placebo‐controlled, double‐blind clinical trial
AIMS: Use of nonsteroidal anti‐inflammatory drugs (NSAIDs) can cause damage to the gastric and duodenal mucosa. Some probiotics have proven useful in ameliorating the harmful side‐effects of NSAIDs. Our aim was to evaluate whether oral administration of Bifidobacterium animalis ssp. lactis 420 (B420...
Autores principales: | Mäkelä, Sanna M., Forssten, Sofia D., Kailajärvi, Marita, Langén, Ville L., Scheinin, Mika, Tiihonen, Kirsti, Ouwehand, Arthur C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291844/ https://www.ncbi.nlm.nih.gov/pubmed/33908058 http://dx.doi.org/10.1111/bcp.14880 |
Ejemplares similares
-
Bifidobacterium animalis ssp. lactis 420 Protects against Indomethacin-Induced Gastric Permeability in Rats
por: Lyra, Anna, et al.
Publicado: (2012) -
Bifidobacterium animalis subsp. lactis 420 for Metabolic Health: Review of the Research
por: Uusitupa, Henna-Maria, et al.
Publicado: (2020) -
Bifidobacterium animalis ssp. Lactis 420 Mitigates Autoimmune Hepatitis Through Regulating Intestinal Barrier and Liver Immune Cells
por: Zhang, Hongxia, et al.
Publicado: (2020) -
Polydextrose with and without Bifidobacterium animalis ssp. lactis 420 drives the prevalence of Akkermansia and improves liver health in a multi-compartmental obesogenic mice study
por: Yde, Christian Clement, et al.
Publicado: (2021) -
The Effect of Delivery Matrix on Bifidobacterium animalis subsp. lactis HN019 Survival through In Vitro Human Digestion
por: Yeung, Nicolas, et al.
Publicado: (2023)